Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (4314)	1/5/1998 1:03:00 AM
From: Gene Voss	Read Replies (2) \| Respond to of 23519

Regarding systemic damage from oral meds.These PDE-5 inhibitors will have wide ranging systemic affects since PDE receptors exist on enzymes in many tissues.Whether any significant long lasting side affects or organ damage results will depend on the patient, the dose,underlying pathology,interactions with other agents and a multitude of unknown factors.Sometime the only answer comes with long term therapy in multiple patient populations. Very little long term data has been presented so the ultimate systemic affects are unknown. <Regarding insidertrading> I've watched this pretty closely and the fact that Lee Wilson has sold so little of his holdings seems to address at least his opinion of the company and its future potential.I would have sold much more in the same postion just to diversify my portfolio so I take his actions as positive. GV.